Drugs / Liposomal paclitaxel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06278870 | Sep 2023 → Jun 2031 expected | HER2 positive breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT05766800 Background | Mar 2023 → Apr 2025 overdue | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05621434 Background | Dec 2022 → Dec 2024 | HER2 positive breast carcinoma | Fujian Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT06102395 Background | May 2023 → Apr 2027 expected | head and neck squamous cell carcinoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| — | NCT07337096 Background | Jan 2026 → Dec 2027 expected | non-small cell lung carcinoma | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal Paclitaxel | “PD-1 inhibitor plus TP or GP regimen chemotherapy (Paclitaxel or Liposomal Paclitaxel + Carboplatin or Cisplatin , nab-paclitaxel + Carboplatin or Cisplatin, Gemcitabine +...” NCT07337096 ↗4“Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer...” NCT06278870 ↗ “Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer...” NCT05621434 ↗ |